摘要
核红系 2 相关因子 (Nrf2) 转录因子/血氧合酶 1 (HO-1) 是重要神经保护反应的关键调节因子,通过驱动各种细胞保护基因的解释来编码抗炎、抗氧化和解毒蛋白.各种研究表明,Nrf2/HO-1 的上调已成为肌萎缩侧索硬化 (ALS) 的潜在治疗方法。肌萎缩侧索硬化是一种运动神经元疾病,其中运动皮层、脑干和皮质脊髓束的上运动神经元和下运动神经元进行性丧失。 Nrf2/HO-1 上调的结果表明,在大脑中,抗氧化能力得到加强。此外,这显示了对肌萎缩侧索硬化中氧化应激的细胞保护作用。一项研究报告了与神经元细胞、少突胶质细胞、小胶质细胞和星形胶质细胞中 Nrf2/HO-1 相关的功能。虽然ALS的发病机制尚不明确,但令人信服。证据表明大脑中的任何功能障碍,如线粒体功能障碍、蛋白质聚集、神经胶质细胞活化、兴奋性毒性和细胞凋亡,这些都会导致类似 ALS 的症状。在这篇综述中,我们主要关注详述 Nrf2/HO-1 的下调,这可能是主要原因,并可能进一步作为 ALS 发展的病理标志。据调查,基于目标的干预措施有限,只能缓解症状,但不能完全治愈疾病。 Nrf2/HO-1 信号通路的失调导致许多生理变化,导致神经系统疾病,包括 ALS。基于上述观点,我们总结了 Nrf2/HO-1 信号在 ALS 中的联合作用,并探索了通过通路调节剂改善疾病的潜在治疗策略。
关键词: 肌萎缩侧索硬化、nrf2/HO-1、少突胶质细胞、小胶质细胞、星形胶质细胞、神经元细胞、细胞凋亡、运动神经元。
Current Molecular Medicine
Title:Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders
Volume: 21 Issue: 8
关键词: 肌萎缩侧索硬化、nrf2/HO-1、少突胶质细胞、小胶质细胞、星形胶质细胞、神经元细胞、细胞凋亡、运动神经元。
摘要: The nuclear erythroid 2-related-factor (Nrf2) transcription factor/hemoxygenase 1 (HO-1) is a key regulator of an important neuroprotection response by driving the interpretation of various cytoprotective gene to encode for anti-inflammatory, antioxidant, and detoxifying proteins. Various studies investigated that the upregulation of Nrf2/HO-1 has become the potential therapeutic approach in amyotrophic lateral sclerosis (ALS). Amyotrophic lateral sclerosis is a motor neuron disease in which there is a progressive loss of upper motor neuron and lower motor neurons of the motor cortex, brain stem, and corticospinal tract. A result of this upregulation of Nrf2/HO-1 indicates that in the brain, anti-oxidant capacity is reinforced. Further, this shows a cytoprotective effect against oxidative stress in amyotrophic lateral sclerosis. A study reported functions associated with the Nrf2/HO-1 in the neuronal cell, oligodendrocytes, microglia, and astrocytes. Although ALS's pathogenesis is not yet clear, but it is compelling. The evidence shows any dysfunction in the brain such as mitochondrial dysfunction, protein aggregation, glial cell activation, excitotoxicity, and apoptosis which gives ALS-like symptoms. In this review, we have mainly focused on detailing the downregulation of Nrf2/HO-1, which may be the prime reason and may further serve as a pathological hallmark for ALS development. As surveyed, there are limited targetbased interventions that only provide symptomatic relief but do not cure the disease completely. Dysregulation of the Nrf2/HO-1 signaling pathway leads to many physiological changes contributing to neurological conditions, including ALS. Based on the above view, we summarized the combined role of Nrf2/HO-1 signaling in ALS and explored potential therapeutic strategies for disease improvement through pathway modulators.
Export Options
About this article
Cite this article as:
Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders, Current Molecular Medicine 2021; 21 (8) . https://dx.doi.org/10.2174/1566524021666210111104920
DOI https://dx.doi.org/10.2174/1566524021666210111104920 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Amyloid Beta Peptide, 4-Hydroxynonenal and Apoptosis
Current Alzheimer Research Brain Nitric Oxide and Its Dual Role in Neurodegeneration / Neuroprotection: Understanding Molecular Mechanisms to Devise Drug Approaches
Current Medicinal Chemistry Subject Index to Volume 1
Current Neurovascular Research Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects
Current Medicinal Chemistry Treatment Strategies of Obsessive-Compulsive Disorder and Panic Disorder/Agoraphobia
Current Topics in Medicinal Chemistry Nutritional Approaches to Modulate Oxidative Stress in Alzheimers Disease
Current Alzheimer Research Human Cognitive and Neuro-Psychiatric Bio-Markers in the Cardiac Peri-Operative Patient
Current Molecular Medicine Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Virus-Based RNA Silencing Agents and Virus-Derived Expression Vectors as Gene Therapy Vehicles
Recent Patents on Biotechnology Editorial (Thematic Issue: Neuroglia as a Central Element of Neurological Diseases: An Underappreciated Target for Therapeutic Intervention)
Current Neuropharmacology Drug Delivery Technologies and Stem Cells for Tissue Repair and Regeneration
Current Pharmaceutical Biotechnology Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Animal Models for Testing Anti-Prion Drugs
Current Topics in Medicinal Chemistry Updating the Chemistry and Biology of Cannabinoid CB2 Receptor – Specific Inverse Agonists
Current Topics in Medicinal Chemistry Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Complex and Differential Glial Responses in Alzheimer´s Disease and Ageing
Current Alzheimer Research